To systematically review the efficacy and safety of Zilongjin Tablet combined with platinum chemotherapy in NSCLC.Methods:Literature was retrieved in CNKI,Wanfang Data,VIP,CBM,Pubmed,Embase and Cochrane library.The search time was up to December 2018.Literature was screened according to inclusion criteria,and available information included was extracted.Meta-analysis was performed by Revman 5.3.Results:A total of 12 studies were included.Compared with the control group,Zilongjin Tablets combined with platinum-containing chemotherapy can increase the stable rate of solid tumors [OR=1.91，95%CI（1.02,3.58），P=0.04],improve the quality of life [OR=8.21，95%CI（3.24,20.78），P<0.000 01],relieve TCM syndrome [OR=246.16，95%CI（70.10,864.39）,P<0.000 01],promote activity of NK cells [MD=8.38，95%CI(6.56,10.19）P<0.000 01] and improve T lymphocyte subpopulation level.Compared with the control group,digestive system in the test group [OR=0.43，95% CI（0.29，0.65）,P<0.000 1],blood system [OR=0.38，95%CI（0.27,0.54,P<0.000 1] and hepatic and renal function [OR=0.40，95% CI(0.19,0.87)，P=0.02].The incidence of adverse reactions of those was low and all are statistically significant.Conclusion:Zilongjin Tablet has better efficacy and safety when used as adjuvant therapy combine with platinum chemotherapy on treating non-small cell lung cancer.It can improve the quality of life of patients,improve the immune function,and have better clinical treatment safety.